Trial · NCT01355159
Outcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Preeclampsia | Participants will be followed from 20+0 weeks of gestational age until 42 days postpartum (after delivery) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Maternal Death | Time Frame: Participants will be followed from 20+0 weeks of gestation until 42 days postpartum (after delivery) | Participants who completed study and were analyzed for primary outcome | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Spontaneous Abortion | Participants will be followed from randomization until 20+0 weeks of gestation | Not all participants had secondary outcome data. Numbers above reflect those that had information available for this secondary outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Placenta Abruption | Participants will be followed from 20+0 weeks of gestation until delivery | Not all participants had secondary outcome data. Numbers above reflect those that had information available for this secondary outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Premature Rupture of Membranes | Participants will be followed from randomization (8-16 weeks' completed gestation) until the onset of labor | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Preterm Birth | Participants will be followed from 20+0 weeks to 36+6 weeks of gestation | Not all participants had secondary outcome data. Numbers above reflect those that had information available for this secondary outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | HELLP (Hemolysis, Elevated Liver Enzyme Levels & Low Platelet Count) | Participants will be followed from 20+0 weeks of gestation until delivery | Not all participants had secondary outcome data. Numbers above reflect those that had information available for this secondary outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Severe Preeclampsia | Participants will be followed from 20+0 weeks of gestation until delivery. | Not all participants had secondary outcome data. Numbers above reflect those that had information available for this secondary outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Antenatal Inpatient Length of Stay | Participants will be followed from date of randomization (8-16 weeks' completed gestation) until admission for delivery | Not all participants had secondary outcome data. Numbers above reflect those that had information available for this secondary outcome. | days | MEAN |
| SECONDARY | Stillbirth | Participants will be followed from 20+0 weeks of gestation up to delivery. | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Intrauterine Growth Restriction (<3rd Percentile) | Participants will be followed from 20+0 weeks of gestation until delivery | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Intrauterine Growth Restriction (<10th Percentile) | Participants will be followed from 20+0 weeks of gestation until delivery | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Neonatal Death | Participants will be followed from birth until 28 days of life | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Perinatal Mortality | Participants will be followed from 20+0 weeks of gestation until 28 days of life. | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Retinopathy of Prematurity | Infants born to the participant will be followed for the duration of hospital stay, or up to 6 weeks | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Early Onset Sepsis | Infants born to the participants will be followed first 48 hours of life. | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Necrotising Enterocolitis | Infants borm to the participants will be followed for the duration of hospital stay, or up to 6 weeks. | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Intraventricular Hemorrhage (IVH) | Time Frame: Infants born to the participants will be followed for the duration of hospital stay, or up to 6 weeks | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Ventilation | Infants born to the participants will be followed for the duration of hospital stay, or up to 6 weeks. | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Need for Oxygen at 28 Days | Infants to the participants will be followed for 28 days after birth. | A total of 2738 infants were born to women recruited into the trial (1364 in folic acid group and 1374 in placebo group). This is an infant outcome. Some participants had missing data for this outcome and therefore were excluded from this analysis. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01355159/outcomes